Dichlorphenamide-13C6 (Synonyms: Diclofenamide-13C6) |
Katalog-Nr.GC47210 |
An internal standard for the quantification of dichlorphenamide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1391054-76-4
Sample solution is provided at 25 µL, 10mM.
Dichlorphenamide-13C6 is intended for use as an internal standard for the quantification of dichlorphenamide by GC- or LC-MS. Dichlorphenamide is a sulfonamide and an orally bioavailable carbonic anhydrase (CA) inhibitor (Kis = 1.20, 38, 50, and 50 nM for the human CA isoforms CAI, CAII, CAIX, and CAXII, respectively).1 It lowers intraocular pressure in rabbits when 50 µl of a 10% solution is applied topically to the eye.2 Dichlorphenamide rescues the potassium deficiency and prevents insulin-induced paralysis in a rat model of familial hypokalemic periodic paralysis when administered at a dose of 5.6 mg/kg per day for ten days.3 Formulations containing dichlorphenamide have been used in the treatment of glaucoma and primary periodic paralysis.
1.Brzozowski, Z., Slawi?ski, J., Innocenti, A., et al.Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XIIEur. J. Med. Chem.45(9)3656-3661(2010) 2.Lotti, V.J., Schmitt, C.J., and Gautheron, P.D.Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbitsGraefes Arch. Clin. Exp. Ophthalmol.222(1)13-19(1984) 3.Tricarico, D., Mele, A., and Conte Camerino, D.Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channelsNeuromuscul. Disord.16(1)39-45(2006)
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *